SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
Autologous, BCMA, CAR-T

Cilta-cel's Review Progresses in the US and EU; Legend Continues Expanding their CARTITUDE Program; Legend Q2 2021 Earnings Call Summary

Here is a brief preview of this blast: On Monday, August 23, Legend released their Q2 2021 results (press release) highlighting the initiation of cilta-cel’s (BCMA CAR-T) review processes for r/r MM in the US and Europe. Furthermore, management noted the expansion of the CARTITUDE program with the initiation of a Ph3 CARTITUDE-5 trial for newly diagnosed MM (NNMM) patients. Below, Celltelligence provides insights on likely US and EU approvals for cilta-cel, while commenting on Legend’s aggressive strategy to move cilta-cel into earlier lines of therapy.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.